This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PETQ or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
by Zacks Equity Research
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
Boston Scientific (BSX) Posts Positive Post-Market Study Data
by Zacks Equity Research
The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.
Why Is Boston Scientific (BSX) Up 5.6% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PETQ or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Comcast, Intuit, Boston Scientific, Freeport-McMoRan and Autodesk
by Zacks Equity Research
Comcast, Intuit, Boston Scientific, Freeport-McMoRan and Autodesk are included in this Analyst Blog.
Top Research Reports for Comcast, Intuit & Boston Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Intuit Inc. (INTU) and Boston Scientific Corporation (BSX).
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
Boston Scientific (BSX) Lags Q3 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -2.27% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Intuit, Diageo, Sony Group, Southern, and Boston Scientific
by Zacks Equity Research
Intuit, Diageo, Sony Group, Southern, and Boston Scientific are included in this Analyst Blog.
Top Research Reports for Intuit, Diageo & Sony
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Intuit Inc. (INTU), Diageo plc (DEO) and Sony Group Corp. (SONY).
Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
by Zacks Equity Research
Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
Why Boston Scientific (BSX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
by Zacks Equity Research
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
by Zacks Equity Research
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
General Electric (GE), Boston Scientific Bond Over Heartcare
by Zacks Equity Research
General Electric's (GE) partnership deal will help the cardiac patients easily avail of heart care treatment.
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
by Zacks Equity Research
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
The Zacks Analyst Blog Highlights Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems
by Zacks Equity Research
Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems are part of Zacks top Analyst Blog.
Top Analyst Reports for Novartis, Duke Energy & Boston Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Duke Energy Corporation (DUK), and Boston Scientific Corporation (BSX).